IDEXX Laboratories, Inc. (NASDAQ:IDXX) Shares Bought by First Trust Advisors LP

First Trust Advisors LP grew its position in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 8.5% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 213,106 shares of the company’s stock after acquiring an additional 16,656 shares during the period. First Trust Advisors LP owned about 0.26% of IDEXX Laboratories worth $88,107,000 at the end of the most recent quarter.

Several other hedge funds have also modified their holdings of the company. Geode Capital Management LLC raised its holdings in IDEXX Laboratories by 1.7% in the 4th quarter. Geode Capital Management LLC now owns 2,297,271 shares of the company’s stock worth $948,279,000 after purchasing an additional 37,734 shares during the period. Franklin Resources Inc. raised its stake in shares of IDEXX Laboratories by 2.5% during the 3rd quarter. Franklin Resources Inc. now owns 1,412,700 shares of the company’s stock worth $675,259,000 after buying an additional 34,305 shares during the period. Invesco Ltd. lifted its position in shares of IDEXX Laboratories by 6.8% during the 4th quarter. Invesco Ltd. now owns 1,160,988 shares of the company’s stock valued at $479,999,000 after buying an additional 74,324 shares in the last quarter. Norges Bank purchased a new position in shares of IDEXX Laboratories during the 4th quarter valued at approximately $412,258,000. Finally, American Century Companies Inc. increased its holdings in IDEXX Laboratories by 30.9% in the 4th quarter. American Century Companies Inc. now owns 809,814 shares of the company’s stock worth $334,810,000 after acquiring an additional 191,385 shares in the last quarter. 87.84% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at IDEXX Laboratories

In other news, EVP George Fennell sold 9,986 shares of the company’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $462.53, for a total value of $4,618,824.58. Following the transaction, the executive vice president now owns 8,176 shares of the company’s stock, valued at $3,781,645.28. This represents a 54.98 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director M Anne Szostak sold 3,000 shares of the stock in a transaction on Friday, February 7th. The stock was sold at an average price of $465.94, for a total value of $1,397,820.00. Following the transaction, the director now owns 3,061 shares of the company’s stock, valued at approximately $1,426,242.34. This represents a 49.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.98% of the stock is currently owned by insiders.

IDEXX Laboratories Stock Up 2.3 %

Shares of IDXX opened at $411.72 on Monday. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $548.88. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The stock has a fifty day simple moving average of $422.37 and a two-hundred day simple moving average of $430.47. The company has a market capitalization of $33.37 billion, a PE ratio of 38.59, a price-to-earnings-growth ratio of 3.41 and a beta of 1.50.

Analyst Ratings Changes

IDXX has been the topic of several recent analyst reports. Barclays increased their price objective on shares of IDEXX Laboratories from $481.00 to $520.00 and gave the company an “overweight” rating in a report on Tuesday, February 4th. StockNews.com cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, April 12th. Morgan Stanley reduced their target price on IDEXX Laboratories from $559.00 to $550.00 and set an “overweight” rating for the company in a report on Wednesday, January 29th. Bank of America lifted their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a “neutral” rating in a research note on Tuesday, February 4th. Finally, Piper Sandler increased their price objective on IDEXX Laboratories from $435.00 to $510.00 and gave the company a “neutral” rating in a research note on Monday, February 10th. Four research analysts have rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $523.75.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.